40 results
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
(collectively, the “FCPA”)) or employee; (iii) violated or is in violation of any provision of the FCPA, UK Bribery Act, any applicable non-U.S. anti-bribery
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
of the FCPA, UK Bribery Act, any applicable non-U.S. anti-bribery statute or regulation or any locally applicable corruption laws; (iv) made any bribe
424B5
SLNO
Soleno Therapeutics Inc
29 Sep 23
Prospectus supplement for primary offering
4:51pm
business restrictions; and
failure to comply with the Foreign Corrupt Practices Act, including its books and records provisions and its anti-bribery
424B5
SLNO
Soleno Therapeutics Inc
27 Sep 23
Prospectus supplement for primary offering
5:26pm
anti-bribery provisions, by maintaining accurate information and control over sales activities and distributors’ activities.
S-27
Any
424B5
h32gi0psg
30 Mar 22
Prospectus supplement for primary offering
5:21pm
424B5
w01s4o
28 Mar 22
Prospectus supplement for primary offering
4:53pm
8-K
EX-1.1
39edih j5y9sde0nkay
16 Jul 21
Entry into a Material Definitive Agreement
4:14pm
8-K
EX-1.1
4fblra1bjfrbkiz4e30y
26 Jun 20
Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock
4:31pm
424B5
r1kfz
25 Jun 20
Prospectus supplement for primary offering
4:01pm
424B5
fz861db7vbrp 1u
23 Jun 20
Prospectus supplement for primary offering
4:06pm
424B5
vyys ugz6sh7b46lw
25 Oct 19
Prospectus supplement for primary offering
12:00am
424B5
ylheh2onbf45avr
22 Oct 19
Prospectus supplement for primary offering
4:24pm
424B3
u3a9h
12 Apr 19
Prospectus supplement
4:41pm